174 related articles for article (PubMed ID: 18648368)
1. Prostaglandin E2 stimulates Fas ligand expression via the EP1 receptor in colon cancer cells.
O'Callaghan G; Kelly J; Shanahan F; Houston A
Br J Cancer; 2008 Aug; 99(3):502-12. PubMed ID: 18648368
[TBL] [Abstract][Full Text] [Related]
2. Retinoic acid morpholine amide (RAMA) inhibits expression of Fas ligand through EP1 receptor in colon cancer cells.
Chen SX; Du SY; Wang YT; Zhao HC; Zhang YL; Yao L
Tumour Biol; 2016 Jan; 37(1):323-9. PubMed ID: 26211005
[TBL] [Abstract][Full Text] [Related]
3. Inflammation and apoptosis in Clostridium difficile enteritis is mediated by PGE2 up-regulation of Fas ligand.
Kim H; Rhee SH; Pothoulakis C; Lamont JT
Gastroenterology; 2007 Sep; 133(3):875-86. PubMed ID: 17854595
[TBL] [Abstract][Full Text] [Related]
4. Prostaglandin E2 upregulates survivin expression via the EP1 receptor in hepatocellular carcinoma cells.
Bai XM; Jiang H; Ding JX; Peng T; Ma J; Wang YH; Zhang L; Zhang H; Leng J
Life Sci; 2010 Jan; 86(5-6):214-23. PubMed ID: 20035770
[TBL] [Abstract][Full Text] [Related]
5. Targeting the EP1 receptor reduces Fas ligand expression and increases the antitumor immune response in an in vivo model of colon cancer.
O'Callaghan G; Ryan A; Neary P; O'Mahony C; Shanahan F; Houston A
Int J Cancer; 2013 Aug; 133(4):825-34. PubMed ID: 23390011
[TBL] [Abstract][Full Text] [Related]
6. The EP4 receptor antagonist, L-161,982, blocks prostaglandin E2-induced signal transduction and cell proliferation in HCA-7 colon cancer cells.
Cherukuri DP; Chen XB; Goulet AC; Young RN; Han Y; Heimark RL; Regan JW; Meuillet E; Nelson MA
Exp Cell Res; 2007 Aug; 313(14):2969-79. PubMed ID: 17631291
[TBL] [Abstract][Full Text] [Related]
7. Fas ligand promotes tumor immune evasion of colon cancer in vivo.
Ryan AE; Shanahan F; O'Connell J; Houston AM
Cell Cycle; 2006 Feb; 5(3):246-9. PubMed ID: 16418579
[TBL] [Abstract][Full Text] [Related]
8. Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells.
Han C; Michalopoulos GK; Wu T
J Cell Physiol; 2006 Apr; 207(1):261-70. PubMed ID: 16331686
[TBL] [Abstract][Full Text] [Related]
9. Prostaglandin E2 stimulates fibronectin expression through EP1 receptor, phospholipase C, protein kinase Calpha, and c-Src pathway in primary cultured rat osteoblasts.
Tang CH; Yang RS; Fu WM
J Biol Chem; 2005 Jun; 280(24):22907-16. PubMed ID: 15833739
[TBL] [Abstract][Full Text] [Related]
10. Influence of antitumor drugs on the expression of Fas system in SW480 colon cancer cells.
Zhu Q; Liu JY; Yang CM; Xu HW; Zhang AZ; Cui Y; Wang HB; Qin CY; Li YQ
Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1071-7. PubMed ID: 16957513
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of prostaglandin E receptor subtype EP3 during colon cancer development.
Shoji Y; Takahashi M; Kitamura T; Watanabe K; Kawamori T; Maruyama T; Sugimoto Y; Negishi M; Narumiya S; Sugimura T; Wakabayashi K
Gut; 2004 Aug; 53(8):1151-8. PubMed ID: 15247185
[TBL] [Abstract][Full Text] [Related]
12. Prostaglandin E2/EP1 signaling pathway enhances intercellular adhesion molecule 1 (ICAM-1) expression and cell motility in oral cancer cells.
Yang SF; Chen MK; Hsieh YS; Chung TT; Hsieh YH; Lin CW; Su JL; Tsai MH; Tang CH
J Biol Chem; 2010 Sep; 285(39):29808-16. PubMed ID: 20647315
[TBL] [Abstract][Full Text] [Related]
13. Role of cytokines in promoting immune escape of FasL-expressing human colon cancer cells.
Xu T; Sun BC; Li Q; Hao XS
World J Gastroenterol; 2005 Jul; 11(25):3915-9. PubMed ID: 15991293
[TBL] [Abstract][Full Text] [Related]
14. Is FAS/Fas ligand system involved in equine corpus luteum functional regression?
Galvao AM; Ramilo DW; Skarzynski DJ; Lukasik K; Tramontano A; Mollo A; Mateus LM; Ferreira-Dias GM
Biol Reprod; 2010 Dec; 83(6):901-8. PubMed ID: 20720169
[TBL] [Abstract][Full Text] [Related]
15. Suppression of FasL expression in tumor cells and preventing TNF-induced apoptosis was better for immune cells survival.
Xu G; Zhang J
J Cancer Res Clin Oncol; 2008 Oct; 134(10):1043-9. PubMed ID: 18461366
[TBL] [Abstract][Full Text] [Related]
16. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas.
Shiraki K; Tsuji N; Shioda T; Isselbacher KJ; Takahashi H
Proc Natl Acad Sci U S A; 1997 Jun; 94(12):6420-5. PubMed ID: 9177233
[TBL] [Abstract][Full Text] [Related]
17. Indomethacin decreases EP2 prostanoid receptor expression in colon cancer cells.
Fujino H; Chen XB; Regan JW; Murayama T
Biochem Biophys Res Commun; 2007 Aug; 359(3):568-73. PubMed ID: 17555711
[TBL] [Abstract][Full Text] [Related]
18. Fas and Fas ligand expression in tumor cells and in vascular smooth-muscle cells of colonic and renal carcinomas.
Peduto Eberl L; Guillou L; Saraga E; Schröter M; French LE; Tschopp J; Juillerat-Jeanneret L
Int J Cancer; 1999 May; 81(5):772-8. PubMed ID: 10328232
[TBL] [Abstract][Full Text] [Related]
19. Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer.
O'Connell J; Bennett MW; O'Sullivan GC; Roche D; Kelly J; Collins JK; Shanahan F
J Pathol; 1998 Nov; 186(3):240-6. PubMed ID: 10211111
[TBL] [Abstract][Full Text] [Related]
20. CC531s colon carcinoma cells induce apoptosis in rat hepatic endothelial cells by the Fas/FasL-mediated pathway.
Vekemans K; Timmers M; Vermijlen D; De Zanger R; Wisse E; Braet F
Liver Int; 2003 Aug; 23(4):283-93. PubMed ID: 12895269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
